Unique technology, Unique market
Xspray Pharma’s unique technology could improve the quality of life, and make it possible for more patients to access improved Protein Kinase Inhibitor (PKI) drugs for treatment of cancer.
-
Latest report
Year End Report 2022 -
Subscribe
Get our latest press releases and reports

Press releases
Press release 2023-03-13
Board member in Xspray Pharma acquires shares from the CEO
Regulatory press release 2023-02-23
Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
Regulatory press release 2023-02-15
Interim Report Fourth Quarter 2022
Press release 2022-12-13
Xspray presents novel scientific data for XS004 in the Chronic Myeloid Leukemia (CML) session at the 2022 Meeting of the American Society of Hematology
Press release 2022-11-30
Xspray Pharma’s drug candidate XS004 granted orphan drug designation in the US for the treatment of acute lymphoblastic leukemia

Xspray Pharma uses its innovative, patented technology to develop amorphous product candidates that are improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Often the original companies have secondary patents that are based on the crystalline forms of the active substance. Since Xspray Pharma’s products are amorphous, they can be marketed as soon as the original companies’ drug substance patents expire. This is a unique opportunity for a favorable market establishment on a multi billion dollar market.

We see a large potential for our product portfolio. Our technology is compatible for most of the 72 US markeded protein kinase inhibitors. The company’s new porduct candidates are being developed in the same manner as the company´s initial product, XS004 dasatinib. The process is reproducible and reduces the effective developing time for future products in our pipeline. This is an exciting time! Per Andersson, CEO